José García G F R P. Epigenetic proling of the antitumor natural product psammaplin A and its analogues[J]. Bioorgan Med Chem, 2011, 19(12): 3637.
[2]
Lindqvist L, Pelletier J. Inhibitors of translation initiation as cancer therapeutics[J]. Future Med Chem, 2009, 1(9): 1709.
[3]
Nguyen T L, Xu X, Gussio R, et al. The assembly-inducing laulimalide/peloruside a binding site on tubulin: molecular modeling and biochemical studies with peloruside A[J]. J Chem Inf Model, 2010, 50(11): 2019.
[4]
Glaser K B, Mayer A M S. A renaissance in marine pharmacology: from preclinical curiosity to clinical reality[J]. Biochem Pharmacol, 2009, 78(5): 440.
[5]
Fukuoka K, Yamagishi T, Ichihara T, et al. Mechanism of action of aragusterol a (YTA0040), a potent anti-tumor marine steroid targeting the G(1) phase of the cell cycle[J]. Int J Cancer, 2000, 88(5):810.
[6]
Yan X, Chen H, Lu X, et al. Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model[J]. Eur J Pharm Sci, 2011, 43(4): 251.
[7]
Kitzen J J, de Jonge M J, Verweij J. Aurora kinase inhibitors[J]. Crit Rev Oncol Hematol, 2010, 73(2): 99.
[8]
Hsiao C J, Ho Y F, Hsu J T, et al. Mana-hox displays anticancer activity against prostate cancer cells through tubulin depolymerization and DNA damage stress[J]. Naunyn Schmiedebergs Arch Pharmacol, 2008, 378(6): 599.
[9]
Bhatnagar I, Kim S K. Marine antitumor drugs: status, shortfalls and strategies[J]. Mar Drugs, 2010, 8(10): 2702.
[10]
Riches L C, Lynch A M, Gooderham N J. Early events in the mammalian response to DNA double-strand breaks[J]. Mutagenesis, 2008, 23(5): 331.
[11]
Ocio E M, Maiso P, Chen X, et al. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks[J]. Blood, 2009, 113(16): 3781.
[12]
Jiang Y, Ahn E Y, Ryu S H, et al. Cytotoxicity of psammaplin A from a two-sponge association may correlate with the inhibition of DNA replication[J]. Bmc Cancer, 2004, 4:70.
[13]
Kizaka-Kondoh S, Tanaka S, Harada H, et al. The HIF-1-active microenvironment: an environmental target for cancer therapy[J].Adv Drug Deliv Rev, 2009, 61(7/8): 623.
[14]
Nagle D G, Zhou Y D. Marine natural products as inhibitors of hypoxic signaling in tumors[J]. Phytochem Rev, 2009, 8(2): 415.
[15]
Liu Y, Liu R, Mao S C, et al. Molecular-targeted antitumor agents 19 furospongolide from a marine Lendenfeldia sp. sponge inhibits hypoxia-inducible factor-1 activation in breast tumor cells[J]. J Nat Prod, 2008, 71(11): 1854.
[16]
Schneiders F L, Scheper R J, von Blomberg B M, et al. Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection[J]. Clin Immunol, 2011, 140(2): 130.
[17]
Giaccone G, Punt C J, Ando Y, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors[J]. Clin Cancer Res, 2002, 8(12): 3702.
[18]
Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69.
[19]
Paul V J, Arthur K E, Ritson-Williams R, et al. Chemical defenses: from compounds to communities[J]. Biol Bull, 2007, 213(3): 226.
[20]
张建业,符立梧.几类重要的海洋抗肿瘤药物研究进展[J].药学学报,2008,43(5):435.
[21]
Simmons T L, Andrianasolo E, McPhail K, et al. Marine natural products as anticancer drugs[J]. Mol Cancer Ther, 2005, 4(2): 333.
[22]
Sun Y, Peng Z L. Programmed cell death and cancer[J]. Postgrad Med J, 2009, 85(1001):134.
[23]
Keen N, Taylor S. Mitotic drivers——inhibitors of the aurora B kinase[J]. Cancer Metastasis Rev, 2009, 28(1/2): 185.
[24]
Kingston D G. Tubulin-interactive natural products as anticancer agents[J]. J Nat Prod, 2009, 72(3): 507.
[25]
Mani S, Macapinlac M J, Goel S, et al. The clinical development of new mitotic inhibitors that stabilize the microtubule[J]. Anticancer Drugs, 2004, 15(6): 553.
[26]
Munoz Couselo E, Perez Garcia J, Cortes J. Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer[J]. Onco Targets Ther, 2011, 4: 185.
[27]
Cortes J, Vahdat L, Blum J L, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine[J]. J Clin Oncol, 2010, 28(25): 3922.
[28]
Swami U, Chaudhary I, Ghalib M H, et al. Eribulin-a review of preclinical and clinical studies[J]. Crit Rev Oncol Hematol, 2012, 81(2): 163.
[29]
Cortes J, Montero A J, Gluck S. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer[J]. Cancer Treat Rev, 2012, 38(2): 143.
[30]
Miller J H, Singh A J, Northcote P T. Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide[J]. Mar Drugs, 2010, 8(4): 1059.
[31]
Hadaschik B A, Ettinger S, Sowery R D, et al. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin[J]. Int J Cancer, 2008, 122(10): 2368.
[32]
Usui T. Actin- and microtubule-targeting bioprobes: their binding sites and inhibitory mechanisms[J]. Biosci Biotechnol Biochem, 2007, 71(2): 300.
[33]
Tadeusz F. Molinski D S. Drug development from marine natural products[J]. Nat Rev Drug Discov, 2009, 8(1): 69.
[34]
Skropeta D, Pastro N, Zivanovic A. Kinase inhibitors from marine sponges[J]. Mar Drugs, 2011, 9(10): 2131.
[35]
Mahadevan D, Plummer R, Squires M S, et al. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors[J]. Ann Onc, 2011, 22(9): 2137.
[36]
Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer[J]. Nat Rev Drug Discov, 2009, 8(7):547.
